Inosiplex is a compound formulation composed of inosine and p-acetaminobenzoic acid （PABA） salt of N,N-dimethylamino-2-propanol （DIP）. This study was to investigate the clinical plasma pharmacokiuetic properties o...Inosiplex is a compound formulation composed of inosine and p-acetaminobenzoic acid （PABA） salt of N,N-dimethylamino-2-propanol （DIP）. This study was to investigate the clinical plasma pharmacokiuetic properties of DIP and PABA after single and multiple oral doses of inosiplex tablets in healthy Chinese volunteers. The established LC/MS/MS method for plasma DIP determination had a linear range of 0.02-10 pg/mL, and the HPLC method for plasma PABA determination had a linear range of 0.0540 pg/mL. Linear pharmacokinetic characteristics were found with single oral doses of 0.5, 1.0 and 2.0 g. No obvious accumulation effects were observed for DIP and PABA.展开更多
A sensitive and selective liquid chromatography-tandem mass spectrometric（LC —MS/MS）method was established to determine 2-oxo-clopidogrel,a crucial intermediate metabolite in human plasma.A chromatographic separati...A sensitive and selective liquid chromatography-tandem mass spectrometric（LC —MS/MS）method was established to determine 2-oxo-clopidogrel,a crucial intermediate metabolite in human plasma.A chromatographic separation was performed on a Sapphire C_（18） column following a liquid-liquid extraction sample preparation with methyl t-butyl ether.Detection was carried out on a triple quadrupole mass spectrometer operated in multiple reaction monitoring（MRM） with an electrospray ionization（ESI）mode.The method was validated in terms of specificity,accuracy,precision and limit of quantification.The calibration curves ranged from 0.50 to 50.0 ng/mL with good linearity.The stability was fully validated with addition of 1,4-dithio-DL-threitol（DTT） into the plasma sample prior to and in the preparation procedure.The validated method was proved to be suitable for use in pharmacokinetic study after single oral administration of 75 mg clopidogrel tablets in human subjects,which could make contribution to intensive study of the clinical drug-drug interactions of clopidogrel and individual treatment.展开更多
基金financially supported by the Fundamental Research Funds for the Central Universities(Grant no.JKP2011008)the Qing Lan Project,and the Program for New Century ExcellentTalents in University(Grant no.NCET-10-0816)
文摘Inosiplex is a compound formulation composed of inosine and p-acetaminobenzoic acid （PABA） salt of N,N-dimethylamino-2-propanol （DIP）. This study was to investigate the clinical plasma pharmacokiuetic properties of DIP and PABA after single and multiple oral doses of inosiplex tablets in healthy Chinese volunteers. The established LC/MS/MS method for plasma DIP determination had a linear range of 0.02-10 pg/mL, and the HPLC method for plasma PABA determination had a linear range of 0.0540 pg/mL. Linear pharmacokinetic characteristics were found with single oral doses of 0.5, 1.0 and 2.0 g. No obvious accumulation effects were observed for DIP and PABA.
文摘A sensitive and selective liquid chromatography-tandem mass spectrometric（LC —MS/MS）method was established to determine 2-oxo-clopidogrel,a crucial intermediate metabolite in human plasma.A chromatographic separation was performed on a Sapphire C_（18） column following a liquid-liquid extraction sample preparation with methyl t-butyl ether.Detection was carried out on a triple quadrupole mass spectrometer operated in multiple reaction monitoring（MRM） with an electrospray ionization（ESI）mode.The method was validated in terms of specificity,accuracy,precision and limit of quantification.The calibration curves ranged from 0.50 to 50.0 ng/mL with good linearity.The stability was fully validated with addition of 1,4-dithio-DL-threitol（DTT） into the plasma sample prior to and in the preparation procedure.The validated method was proved to be suitable for use in pharmacokinetic study after single oral administration of 75 mg clopidogrel tablets in human subjects,which could make contribution to intensive study of the clinical drug-drug interactions of clopidogrel and individual treatment.
